In recent years, with the use of direct-acting antivirals (DAA) in the treatment of chronic hepatitis C (CHC), the success rate has exceeded 90%. The implementation of these strong therapies has reduced the role of monitoring therapy with HCV RNA tests. The aim of this study is to compare the HCV core antigen test with HCV RNA in terms of correlation, effectiveness and cost in patients who started DAA and to evaluate the usability of HCV Ag as a routine laboratory test.This study includes 76 patients with CHC. Patients with positive HCV RNA, over 18 years old and who will initiate DAA are included. HCV Ag level was studied in all samples by using ARCHITECT core antigen measurement Abbott method. HCV RNA and anti-HCV levels compared with HCV Ag levels. When compared before and after treatment, HCV RNA level, HCV Ag level were found to be significantly different (p <0.001). Before treatment, HCV RNA and HCV Ag levels were found to be positive correlations (correlation coefficient:0,419). It has been demonstrated in the our study that HCV Ag measurement is a very successful and cost effective in detecting viremic patients and evaluating virological response, which are the two most important factors in the management of CHC.

No abstract

Potent antivirals are used for the treatment of hepatitis B infection. A 38-year-old female patient whose hepatit B virus (HBV) viral load was suppressed under tenofovir disoproxil fumarate treatment but had a viral flare during in vitro fertilization (IVF) treatment is presented. Although HBV DNA was negative continuously in the controls, an increase in HBV DNA was observed during IVF treatment. Hepatitis B has been isolated from many extrahepatic tissues. Ovarian stimulation is likely to increase viral replication. Therefore, it is essential to check HBV DNA periodically to prevent vertical transmission.

Background: The COVID-19 pandemic has resulted in more than 31 million cases diagnosed and 965,000 deaths as of September 21, 2020. As the number of cases increases, clinical conditions such as prolonged viral release, reinfection, and reactivation are being encountered more frequently.Case presentation: This article presents a case who was reinfected with COVID-19 and developed a more severe second disease unlike other cases in the literature.Conclusions: Reinfection in a splenectomy case may help researchers understand the pathogenesis of the disease and can be a guide for the development of vaccines and new treatments.